Cellular Aging: Senescence, Telomeres, Mitochondrial Dysfunction and Disease

Learning outcomes

• Define cellular ageing, replicative senescence, quiescence and apoptosis.
• Explain the major biological mechanisms of ageing: genomic instability, telomere attrition, epigenetic change, loss of proteostasis, mitochondrial dysfunction, nutrient-sensing changes, stem-cell exhaustion and altered intercellular communication.
• Describe the role of DNA damage, ROS, autophagy, mTOR, AMPK, sirtuins, p53/p21 and p16/RB pathways.
• Recognise morphology and laboratory markers of senescent and aged cells.
• Explain how senescence-associated secretory phenotype (SASP) contributes to inflammation, fibrosis, cancer and tissue dysfunction.
• Relate ageing mechanisms to organ-specific disease and emergency presentations.
• Distinguish evidence-based prevention from unproven “anti-ageing” claims.

1. Core concepts

State	Meaning	Can proliferation resume?	Example
Quiescence	Reversible resting state caused by lack of growth signals or nutrients.	Usually yes when stimulation returns.	Hepatocytes after the liver reaches normal mass.
Senescence	Durable cell-cycle arrest with altered metabolism and secretory behaviour after stress or repeated division.	Generally no under physiologic conditions.	Replicative senescence of fibroblasts.
Apoptosis	Regulated cell death with caspase activation and phagocytic clearance.	No; the cell is dead.	Removal of irreparably damaged cells.
Cellular ageing	Cumulative decline in repair, energy, proteostasis and adaptation, with or without senescence.	Capacity declines variably.	Ageing cardiomyocytes with lipofuscin and mitochondrial damage.

2. The major hallmarks of cellular ageing

The modern hallmarks framework groups interconnected processes. A cell rarely ages through one pathway alone; DNA damage can impair mitochondria, mitochondrial ROS can damage DNA, and chronic SASP inflammation can exhaust stem cells.

Hallmark	Cellular change	Clinical consequence
Genomic instability	DNA mutations, strand breaks, defective repair and chromosomal rearrangements.	Cancer, cell-cycle arrest, organ dysfunction.
Telomere attrition	Progressive shortening of chromosome ends with repeated replication or stress.	Stem-cell exhaustion, marrow failure and pulmonary/liver disease in telomere syndromes.
Epigenetic alterations	Changed DNA methylation, histone modification, chromatin remodelling and transposable-element activity.	Abnormal gene expression and loss of cell identity.
Loss of proteostasis	Misfolding, impaired chaperones, defective ER quality control and reduced proteasome/autophagy.	Neurodegeneration, ER stress and inclusion bodies.
Disabled autophagy	Damaged organelles and proteins accumulate because recycling is inadequate.	Mitochondrial dysfunction, inflammation and loss of reserve.
Mitochondrial dysfunction	Reduced oxidative phosphorylation, mtDNA mutations, altered dynamics and ROS.	Energy failure, sarcopenia, cardiac dysfunction and poor stress tolerance.
Deregulated nutrient sensing	Altered insulin/IGF-1, mTOR, AMPK and sirtuin signalling.	Metabolic syndrome, impaired repair and accelerated ageing phenotypes.
Mitochondrial communication	Damaged mitochondria release DAMPs and inflammatory signals.	Chronic inflammation and immune dysfunction.
Cellular senescence	Stable growth arrest with SASP production.	Fibrosis, tumour suppression initially, tissue dysfunction if persistent.
Stem-cell exhaustion	Reduced self-renewal and regenerative capacity.	Poor wound healing, anaemia, sarcopenia and organ failure.
Altered intercellular communication	Chronic low-grade inflammatory, endocrine and neural changes.	Frailty, atherosclerosis and immunosenescence.

3. Genomic instability and DNA damage

DNA is damaged continuously by replication errors, ROS, ultraviolet radiation, toxins, inflammation and spontaneous chemical changes. Young cells use nucleotide excision repair, base-excision repair, mismatch repair, homologous recombination and non-homologous end joining. With age, repair capacity declines and mutations accumulate.

3.1 DNA-damage response

• ATM/ATR kinases sense double- and single-strand damage.
• p53 induces p21, pauses the cell cycle and coordinates repair.
• If damage is irreparable, p53 can activate BAX/PUMA and apoptosis.
• Persistent damage activates p16^INK4a/RB and stable senescence.
• Chromosome mis-segregation, micronuclei and cytosolic DNA can activate cGAS–STING inflammation.

3.2 Clinical links

Defective repair causes premature ageing syndromes and cancer predisposition. In older patients, a lower reserve of intact cardiomyocytes, neurons, renal tubular cells and stem cells means that a short episode of hypoxia or infection may produce a disproportionate functional decline.

4. Telomere attrition

Telomeres are repetitive DNA–protein structures that protect chromosome ends. Most somatic cells lack sufficient telomerase, so telomeres shorten with repeated replication. Critically short telomeres activate DNA-damage signalling, p53/p21 and p16/RB pathways, producing senescence or apoptosis.

4.1 Telomerase

Telomerase maintains telomeres in germ cells, many stem cells and most cancers. Excess telomerase supports unlimited tumour-cell proliferation; insufficient telomerase causes premature exhaustion of regenerative compartments.

4.2 Telomere biology disorders

• Bone-marrow failure and cytopenias.
• Pulmonary fibrosis and liver disease.
• Short stature, premature greying and mucocutaneous findings.
• Increased risk from infection, bleeding and organ failure during acute stress.

5. Epigenetic and chromatin changes

Ageing alters DNA methylation (“epigenetic clock”), histone acetylation/methylation, nucleosome positioning and chromatin organisation. Heterochromatin loosens, repetitive DNA becomes active and gene expression drifts. These changes can silence repair pathways, alter inflammation and make cells more vulnerable to environmental stress.

• Loss of heterochromatin: reduces genome stability and cell identity.
• Altered histone marks: change repair, metabolism and inflammatory gene expression.
• Non-coding RNAs: microRNAs and long non-coding RNAs alter translation and senescence signalling.
• Transposable elements: reactivation can generate DNA breaks and innate immune activation.

6. Loss of proteostasis

Proteostasis is the balance of protein synthesis, folding, trafficking and degradation. Ageing reduces molecular chaperones, proteasome activity, ER quality control and autophagy. Misfolded proteins aggregate and activate chronic unfolded-protein responses.

Defect	Result	Example
ER stress	PERK, IRE1 and ATF6 pathways initially slow translation and increase chaperones; persistent stress activates CHOP and apoptosis.	Pancreatic beta-cell failure, neurodegeneration.
Proteasome decline	Oxidised and ubiquitinated proteins accumulate.	Inclusion bodies in neurodegenerative disease.
Autophagy decline	Damaged mitochondria and protein aggregates persist.	Sarcopenia, cardiac ageing and liver injury.
Extracellular aggregation	Misfolded proteins deposit in tissue and alter architecture.	Amyloid diseases.

7. Mitochondrial dysfunction and oxidative stress

Mitochondria age through mtDNA mutations, altered fusion/fission, impaired mitophagy and electron-transport-chain defects. Less ATP is produced, while electron leakage generates ROS. Damaged mitochondria release mitochondrial DNA and cardiolipin, which act as DAMPs.

• Energy reserve falls: cells fail sooner during hypoxia, sepsis or increased workload.
• ROS rises: lipids, proteins and DNA are oxidised.
• Calcium buffering weakens: arrhythmias and mitochondrial permeability transition become more likely.
• Mitophagy declines: defective mitochondria accumulate.
• Inflammation increases: cGAS–STING and NLRP3 pathways detect mitochondrial damage.

8. Nutrient sensing and metabolic ageing

Pathway	Normal role	Age-related dysregulation
Insulin/IGF-1	Growth, nutrient use and protein synthesis.	Insulin resistance, hyperglycaemia and impaired repair.
mTOR	Growth and anabolic protein synthesis.	Chronic activation suppresses autophagy and may accelerate ageing.
AMPK	Senses low energy; promotes catabolism and autophagy.	Reduced response limits metabolic flexibility.
Sirtuins	NAD+-dependent regulation of mitochondria, chromatin and stress responses.	NAD+ decline impairs repair and mitochondrial function.

Calorie restriction and exercise influence these pathways in model organisms, but no supplement or “longevity” product has been proven to reverse human ageing. Translate evidence cautiously and prioritise established prevention.

9. Cellular senescence

9.1 Definition and triggers

Senescence is a durable cell-cycle arrest in a living, metabolically active cell. Triggers include repeated replication, telomere shortening, oncogene activation, DNA damage, oxidative stress, radiation, chemotherapy and mitochondrial dysfunction.

9.2 Signalling pathways

• p53–p21 pathway: DNA damage and stress activate p53, which induces p21 and blocks cyclin-dependent kinases.
• p16^INK4a–RB pathway: p16 inhibits CDK4/6, maintains RB-mediated repression and locks the cell in G1 arrest.
• mTOR and inflammatory pathways: regulate cell size, metabolism and SASP production.

9.3 Senescence-associated secretory phenotype (SASP)

Senescent cells release IL-6, IL-8, TNF, TGF-β, chemokines, growth factors, matrix metalloproteinases and extracellular vesicles. SASP can recruit immune cells and reinforce senescence in neighbours.

Beneficial short-term role	Harmful chronic role
Stops proliferation of a cell with oncogenic or DNA damage.	Persistent inflammatory signalling and fibrosis.
Helps recruit immune cells to remove damaged cells.	Degrades extracellular matrix and impairs tissue architecture.
Supports wound-healing signalling when transient.	Promotes tumour microenvironment and therapy resistance.

9.4 Senescence versus quiescence

Quiescent cells are reversible and re-enter the cycle when growth signals return. Senescent cells have persistent cell-cycle arrest, enlarged flattened morphology, altered chromatin, increased lysosomal activity and SASP. Both states can express some overlapping markers, so no single test is definitive.

10. Stem-cell exhaustion and impaired regeneration

Stem cells maintain tissues by self-renewing and producing differentiated progeny. Ageing reduces their number, niche support and ability to respond to injury. Chronic inflammation, telomere shortening, mitochondrial dysfunction and altered extracellular matrix contribute.

• Bone marrow: anaemia, reduced immune-cell diversity and impaired platelet recovery.
• Skeletal muscle: sarcopenia and delayed recovery after immobilisation or sepsis.
• Skin: thin skin, poor barrier function and slow wound healing.
• Intestine: reduced regenerative reserve after infection, surgery or chemotherapy.
• Brain: limited neuronal replacement and reduced synaptic plasticity.

11. Morphology and laboratory markers

Finding	Interpretation	Limitations
Cell enlargement and flattened shape	Common in senescence.	Also occurs in differentiation and stress.
SA-β-gal activity	Increased lysosomal β-galactosidase at pH 6.	Not unique to senescence; assay conditions matter.
p16INK4a, p21	Cell-cycle arrest pathways.	Can rise transiently after acute DNA damage.
Loss of Ki-67/BrdU incorporation	Reduced proliferation.	Cannot alone separate quiescence from senescence.
γH2AX foci	Persistent DNA-damage response.	Also appears in acute injury and cancer.
Lipofuscin	Cumulative oxidative and lysosomal residue.	Marker of age/stress, not a specific disease.
SASP cytokines	Inflammatory secretory phenotype.	Highly variable between cell types and stimuli.

12. Organ-specific effects of ageing

12.1 Cardiovascular system

Arterial stiffening, endothelial dysfunction, mitochondrial decline and cardiomyocyte loss reduce cardiovascular reserve. The older heart tolerates tachycardia, hypoxia and fluid shifts poorly. A small infarct, infection or anaemia may precipitate heart failure.

12.2 Nervous system

Neuronal loss, reduced synaptic plasticity, impaired proteostasis and microglial senescence contribute to cognitive decline and neurodegeneration. Fever, hypoxia, hypoglycaemia and medications can produce delirium because reserve is limited.

12.3 Kidney

Nephron loss, vascular sclerosis, tubular senescence and reduced concentrating ability decrease renal reserve. Acute kidney injury develops more readily during dehydration, nephrotoxin exposure or sepsis.

12.4 Immune system

Immunosenescence reduces naïve T-cell output and vaccine responses while chronic low-grade inflammation (“inflammaging”) rises. Older patients may have severe infection without high fever or leukocytosis.

12.5 Skin and connective tissue

Reduced collagen, elastin, fibroblast function and angiogenesis thin the skin and delay wound healing. Pressure injury and infection risk increase during immobilisation.

13. Clinical implications and emergency medicine

1. Lower physiologic reserve: older patients may decompensate rapidly with modest hypoxia, bleeding, infection or electrolyte disturbance.
2. Atypical presentation: blunted fever, pain or tachycardia may delay recognition of sepsis, myocardial infarction or bowel ischaemia.
3. Medication vulnerability: reduced renal/hepatic clearance and polypharmacy raise toxicity risk.
4. Delayed repair: wounds, fractures and pressure injuries need prevention, early mobilisation and nutrition.
5. Inflammaging: baseline cytokine elevation complicates interpretation of CRP, ferritin and other markers.
6. Frailty: a small stressor can trigger a cascade from delirium to immobility, malnutrition, infection and organ failure.

14. Prevention and evidence-based healthy ageing

• Regular aerobic and resistance exercise preserves mitochondrial function, muscle and insulin sensitivity.
• Balanced nutrition with adequate protein, fibre and micronutrients supports repair; avoid severe fasting in frail patients.
• Do not smoke; limit alcohol and prevent occupational toxin exposure.
• Control blood pressure, diabetes, lipids and chronic inflammatory disease.
• Vaccination, sleep, social connection and cognitive activity support immune and neurological health.
• Prevent falls, pressure injury, dehydration and medication-related harm.
• Investigational senolytics, NAD boosters, rapamycin-like approaches and supplements require clinical evidence before routine use; they are not substitutes for proven prevention.

15. Applied cases

Case 1: Frailty and sepsis

An older adult with pneumonia is confused, mildly tachycardic and hypotensive but afebrile. Immunosenescence and altered cytokine signalling can blunt fever and leukocytosis. Treat the clinical syndrome promptly, obtain cultures without delaying antimicrobials when indicated, assess perfusion and search actively for organ dysfunction.

Case 2: Delirium after surgery

Reduced neuronal reserve, inflammation, sleep disruption, pain, hypoxia, anticholinergic medication and renal impairment interact. Senescent microglia and impaired blood–brain barrier function may amplify the response. Search for reversible causes rather than labelling delirium as “normal ageing.”

Case 3: Delayed wound healing

An immobile patient develops a sacral pressure injury. Senescent fibroblasts, reduced angiogenesis, malnutrition and impaired perfusion delay repair. Relieve pressure, improve nutrition, assess infection and vascular supply, and coordinate wound-care and rehabilitation teams.

16. Cellular ageing versus cancer

Senescence is initially tumour-suppressive because it prevents a damaged cell from dividing. However, if senescent cells accumulate, SASP can promote neighbouring proliferation, angiogenesis, immune evasion and metastatic niches. Cancer cells often bypass senescence by disabling p53, p16/RB, telomere checkpoints or apoptotic pathways.

17. Quick self-test

1. How is senescence different from quiescence?
   Answer: Quiescence is reversible resting; senescence is durable growth arrest with altered metabolism and usually SASP.
2. Name four hallmarks of ageing.
   Answer: Any four of genomic instability, telomere attrition, epigenetic alteration, loss of proteostasis, mitochondrial dysfunction, disabled autophagy, deregulated nutrient sensing, cellular senescence, stem-cell exhaustion and altered communication.
3. Which two pathways enforce senescence arrest?
   Answer: p53–p21 and p16^INK4a–RB.
4. What is SASP?
   Answer: Senescence-associated secretory phenotype: cytokines, chemokines, growth factors and proteases released by senescent cells.
5. Why do older patients decompensate with a modest insult?
   Answer: Reduced organ, stem-cell, mitochondrial and immune reserve leaves less capacity to compensate.
6. Why is SA-β-gal not sufficient to diagnose senescence?
   Answer: It can rise in other states and should be combined with arrest markers, morphology and SASP evidence.
7. Can senescence be beneficial?
   Answer: Yes; transient senescence limits damaged-cell proliferation and assists wound repair, but persistent SASP is harmful.
8. What emergency principle follows from ageing biology?
   Answer: Identify and treat hypoxia, infection, shock, electrolyte disturbance and medication toxicity early because reserve is limited.

18. Take-home summary

Selected references

• NCBI Bookshelf: Cell Injury, Cell Death and Adaptations
• Hallmarks of Aging: An Expanding Universe
• NCBI Bookshelf: Cellular Senescence
• NCBI Bookshelf: Telomere Biology Disorders
• WHO: Ageing and health

Educational note: This resource supports learning and clinical reasoning. Current local protocols, senior supervision and national guidelines take precedence in patient care.